We've detected you are on Internet Explorer. For the best Barrons.com experience, please update to a modern browser.GoogleFirefox
Sign In

This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.

https://www.barrons.com/articles/pfizer-ceo-talks-about-covid-vaccines-and-what-comes-next-i-think-we-are-undervalued-51637263567

Pfizer CEO Talks About Covid Vaccines and What Comes Next: ‘I Think We Are Undervalued.’

By
Josh Nathan-Kazis
  • Order Reprints
  • Print Article

Albert Bourla, the CEO of Pfizer, is perhaps the most sought-after corporate executive in the world this fall. His company’s Covid-19 vaccine is in demand around the globe, and new data on his company’s Covid-19 pill has shaken the market. At the same time, Bourla and Pfizer, which he has led since 2019, are under growing pressure over the vastly unequal global distribution of Covid-19 vaccines.

Last weekend, Barron’s argued in a magazine feature that the dual successes of Pfizer’s Covid-19 vaccine and its Covid-19 oral antiviral...

Copyright ©2021 Dow Jones & Company, Inc. All Rights Reserved

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.